Every Form 4 that Eli Lilly and Company (LLY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LLY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LLY filings page.
Lilly Endowment Inc., a 10% owner of Eli Lilly and Company (LLY), reported open-market sales of common stock. On November 17, 2025, it sold 7,789 shares at a weighted average price of $1,030.448 per share and 2,097 shares at a weighted average price of $1,031.526 per share, in multiple transactions within narrow price ranges. Following these sales, Lilly Endowment Inc. beneficially owned 92,872,191 shares of Eli Lilly common stock, held directly.
Eli Lilly & Co. (LLY) disclosed that a major shareholder reported multiple open-market sales of common stock on 11/14/2025. The transactions, all coded as sales, included blocks of 103,871, 55,908, 17,567, and 949 shares at weighted average prices between $1,030.00 and $1,033.39 per share. After these trades, the reporting person directly beneficially owned 92,882,077 Eli Lilly shares. The prices reported reflect weighted averages for multiple trades within the stated price ranges.
Eli Lilly (LLY) reported insider sales on a Form 4. On 11/13/2025, the reporting person sold 45,246 shares of common stock at a weighted average price of $1,030.21, and 1,360 shares at a weighted average price of $1,031.777. The filing notes these were executed in multiple trades within the stated price ranges. Following the transactions, the reporting person beneficially owned 93,060,372 shares.
Eli Lilly (LLY) reported an insider transaction: the company’s SVP, Finance, & CAO sold 1,000 shares of common stock at $1,010.50 per share on November 13, 2025 (transaction code S).
The filing states the trade was made under a Rule 10b5-1 trading plan adopted on November 20, 2024. Following the sale, the reporting person beneficially owns 2,839.659 shares directly and 1,727.9 shares indirectly through a 401(k).
Eli Lilly (LLY) reported insider activity on a Form 4 showing multiple open‑market sales of common stock on 11/12/2025. The transactions were executed in several tranches at weighted‑average prices disclosed in footnotes.
Following the reported sales, the reporting person beneficially owned 93,106,978 shares, held directly. Footnotes note the sales occurred across price ranges from $1,001.213 to $1,021.661, with the reporting person able to provide detailed trade breakdowns upon request.
Eli Lilly (LLY): Insider transaction reported. A reporting person filed a Form 4 disclosing multiple open‑market sales of Eli Lilly common stock on November 11, 2025. Each line item is coded “S” for sale and reflects a weighted average price, with individual trades occurring within the disclosed ranges.
Reported weighted average prices spanned approximately $972.269 to $999.088, with footnotes stating underlying trade ranges from $972.00 to $999.49 per share across the listed transactions. Following these sales, the reporting person beneficially owned 93,411,978 shares, held directly.
Eli Lilly & Co (LLY) reported insider transactions on 11/10/2025. The reporting person executed three open-market sales: 12,864 shares at a weighted average price of $972.168 (range $972.00–$972.87); 3,887 shares at $973.626 (range $973.025–$973.95); and 118 shares at $974.089 (range $974.065–$974.14).
After these transactions, the reporting person beneficially owned 93,695,109 shares, held directly.
Eli Lilly (LLY) CEO David A. Ricks reported a code G transfer of 24,750 shares of common stock on 11/10/2025 at a stated price of $0. Following the transaction, he directly owns 515,166.167 shares.
He also reports indirect holdings, including 6,685 shares by the David A. Ricks 2025 GRAT, 54,117 shares by the 2022 GRAT, 300 shares by a trust, 68,656 shares by the David A. Ricks SLAT, and 7,305.09 shares in a 401(k). The footnotes note a transfer of 6,685 shares to the 2025 GRAT on September 9, 2025.
Eli Lilly (LLY) officer (EVP, CS&PO & Pres. LRL) reported a Code G transaction of 179 shares of common stock on 11/10/2025 at a reported price of $0.
Following the transaction, the officer beneficially owned 137,481.112 shares directly. Indirect holdings were reported as 72,359 shares by a trust, 547 shares by a spouse, and 2,710 shares by a spouse’s SLAT, subject to a standard pecuniary interest disclaimer.
The filing notes a 200‑share correction to reconcile these holdings with a submission filed on August 12, 2025.
Lilly Endowment Inc., a reporting person for Eli Lilly and Company (LLY), reported multiple open‑market sales of common stock on 11/05/2025, totaling 40,432 shares across eight transactions coded “S.”
The trades executed at weighted‑average prices with ranges disclosed from $947.18 to $955.41. Following these transactions, the reporting person beneficially owned 93,711,978 shares with direct ownership.
Eli Lilly & Co (LLY): A reporting person identified as a director and 10% owner reported open‑market sales of common stock on 11/05/2025 across 30 separate transactions. The trades were executed at weighted‑average prices disclosed by tranche, with individual price ranges noted in the footnotes.
Following these sales, the reporting person directly beneficially owned 93,752,410 shares. The footnotes show sale price ranges spanning from $910.90 to $947.06 per share across the listed tranches. The remark states this is the first of two Forms 4 filed the same day, covering transactions #1–#30 of 38 total.
Lilly Endowment Inc., a director of Eli Lilly (LLY), reported selling 526 shares of common stock on 11/04/2025 with transaction code S. The sale was executed at a weighted average price of $910.719.
The shares were sold in multiple trades at prices ranging from $910.59 to $911.00. After this transaction, the reporting person beneficially owned 93,931,452 shares, held directly.
Lilly Endowment Inc., a director of Eli Lilly (LLY), reported open‑market sales totaling 300,000 shares of common stock on 11/03/2025.
The trades were executed in multiple tranches at weighted average prices with reported ranges from $877.00 to $901.295 per share, as detailed in footnotes. Following these transactions, the reporting person beneficially owned 93,931,978 shares directly.
Eli Lilly (LLY): insider transaction reported. On 10/31/2025, the reporting person executed open-market sales of common stock across multiple tranches totaling 301,342 shares. The weighted average prices for each tranche reflected ranges from $862.00 to $869.9057, as disclosed in footnotes. Following these transactions, the reporting person beneficially owned 94,231,978 shares, held directly.
The sales were recorded as code “S” and reported with weighted average prices for each tranche; detailed per-trade pricing within the stated ranges is available upon request, according to the disclosure. The filing was signed “/s/ Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.”
Eli Lilly (LLY) reported an insider transaction by a director on 10/20/2025. The filing shows an acquisition of 6.129 shares of common stock at $808.96 per share, bringing the director’s direct beneficial ownership to 2,728.14 shares.
According to the footnote, the acquired amount was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person’s separation from service.
Eli Lilly (LLY) director reported a routine equity accrual. On 10/20/2025, the director acquired 18.336 shares of common stock at $808.96 per share, recorded as an “A” (acquisition). Following this transaction, the director beneficially owns 16,474.296 shares, held directly.
The filing notes these shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common shares after the director’s separation from service.
Eli Lilly (LLY) director Mary Lynne Hedley reported an acquisition of 12.259 shares of common stock on 10/20/2025 at $808.96 per share. The filing states the shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common stock following her separation from service.
After the transaction, beneficial ownership stood at 2,015.828 shares held directly and 98 shares held indirectly by trust.
Eli Lilly (LLY) director transaction: On 10/20/2025, director J. Erik Fyrwald reported acquiring 12.259 shares at $808.96. The filing notes the director elected to defer cash compensation into stock units under the Lilly Directors' Deferral Plan, to be settled in common shares after separation from service. Following the entry, beneficial ownership stands at 74,763.656 shares, held directly.
Eli Lilly (LLY) director reported acquiring 14.525 shares of common stock on 10/20/2025 at $808.96 per share. The award was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares following the director’s separation from service. After the transaction, beneficial ownership was 55,151.946 shares directly and 758 shares indirectly by trust.
Eli Lilly (LLY) insider transaction: A reporting person disclosed open‑market sales of Eli Lilly common stock on 10/10/2025. The filer sold 468 shares at a weighted average price of $862.34 (prices ranged from $862.00 to $862.74) and 3,190 shares at a weighted average price of $863.369 (prices ranged from $863.00 to $863.995). Following these transactions, the filer directly owned 94,533,320 shares. The form was signed by Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc.
Lilly Endowment Inc., a director-related reporting person, sold a total of 10,602 shares of Eli Lilly & Co common stock on 10/09/2025. The Form 4 lists eight separate sale entries with weighted-average prices for each block; the reported trade price ranges span from $848.09 up to $857.26. After these transactions, the reporting person beneficially owns 94,536,978 shares directly. Each sale line notes the reporting person can provide detailed per-price quantities on request, and the Form 4 was signed by Peter A. Buck on behalf of Lilly Endowment Inc.
Lilly Endowment Inc. reported the sale of 101,420 shares of Eli Lilly & Co. (LLY) on 10/08/2025 via multiple transactions at weighted-average prices in the range of $848.00 to $856.00. After these disposals, the reporting person shows beneficial ownership of 94,547,580 shares, held indirectly. The filing is a standard Section 16 Form 4 showing routine disposition activity by an entity identified as a director-related reporting person; the signature is provided by a vice president acting on behalf of the endowment.
Lilly Endowment Inc. reported a sale of 26,795 shares of Eli Lilly & Co. common stock on 10/07/2025. The shares were sold at a weighted average price of $848.009, with individual trade prices ranging from $848.00 to $848.32. After the transaction the reporting person beneficially owned 94,649,000 shares, held directly. The Form 4 was signed by Peter A. Buck on 10/08/2025. The filing discloses no derivative holdings and includes an offer to provide a breakdown of the number of shares sold at each price within the reported range.
Lilly Endowment Inc., a reporting person and director-related holder, sold a total of 161,183 shares of Eli Lilly & Co (LLY) on 10/06/2025. The Form 4 lists eight separate sale line items with weighted-average prices reported in footnotes, ranging across price bands from $848.00 up to $856.375. After these transactions, the reporting person’s beneficial ownership is shown as 94,675,795 shares (reported as direct ownership). The Form 4 is signed by Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc., and discloses that full per-price breakdowns are available upon request.
Lilly Endowment Inc. reported multiple open-market disposals of Common Stock of Eli Lilly & Co (LLY) executed on 10/03/2025. The filings list a sequence of sales that reduced beneficial ownership from 95,025,096 shares to 94,836,978, a net decrease of 188,118 shares. Individual sale lots ranged from 200 to 31,102 shares at reported weighted-average prices in successive buckets from $821.00 up to $847.63, with explanatory footnotes showing transaction price ranges within each bucket. The Form 4 is signed by Diane M. Stenson on behalf of Lilly Endowment Inc.